Why the study?
Does hyperlipidemia alter the serum protein binding of propofol compared to normolipemic states?
Does hyperlipidemia alter the serum protein binding of propofol compared to normolipemic states?
Propofol binds extensively to lipoproteins, and elevated serum cholesterol and triglycerides significantly decrease its free fraction, which may impact anesthetic dosing and efficacy.
Reduced unbound propofol in hyperlipidemia may affect dosing; this Level 5 observation leaves open clinical relevance pending prospective data.
The protein binding of propofol was investigated in vitro in isolated lipoprotein fractions (very low-density lipoprotein [VLDL], low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) and in serum samples from the following subjects: healthy normolipemic volunteers (n = 16), hyperlipidemic subjects diagnosed with familiar polygenic hypercholesterolemia (n = 26) showing high levels of cholesterol, and elderly subjects (n = 15). Protein binding was determined by using ultrafiltration, and the concentration of unbound propofol was measured by using liquid chromatography. Levels of total cholesterol, triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol, albumin, and alpha1-acid glycoprotein were also measured. Propofol was extensively bound to the three lipoprotein fractions (88% +/- 2% to VLDL, 93% +/- 1% to LDL, and 91% +/- 4% to HDL). The percentage of unbound propofol was significantly decreased (P < 0.0001) in hyperlipidemic (0.88% +/- 0.20%) individuals whose levels of cholesterol and triglycerides were increased versus healthy subjects (1.26% +/- 0.22%), whereas no significant difference was found in the elderly group (1.12% +/- 0.23%). A positive relationship was found between serum protein binding of propofol and lipid levels. Multiple regression analysis, including all subjects, showed that changes in the levels of total cholesterol and triglycerides explained approximately 62% of the variability in the serum protein binding of propofol. These results stress the importance of triglycerides and cholesterol in the serum protein binding of propofol. We therefore suggest that these variations in lipid levels, and consequently in protein binding, may influence anesthetic practice with propofol. Implications: We investigated the effect of serum lipids in the protein binding of propofol. We found that propofol binds extensively to all lipoprotein fractions. Propofol binding showed a significant relationship with the serum levels of cholesterol and triglycerides. (Anesth Analg 1998;87:1147-51)
No takes yet. Share an insight, caveat, or question.
Zamacona et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: